Your Trusted Brand for Over 35 Years

Daily News

Researchers at University of Rome Sapienza Target Malignant Mesothelioma (In Vitro and In Vivo Anti-tumoral Effects of the Flavonoid Apigenin in...

Cancer Weekly

07-17-17

Researchers at University of Rome Sapienza Target Malignant Mesothelioma (In Vitro and In Vivo Anti-tumoral Effects of the Flavonoid Apigenin in Malignant Mesothelioma)

By a News Reporter-Staff News Editor at Cancer Weekly -- Research findings on Oncology - Malignant Mesothelioma are discussed in a new report. According to news reporting originating from Rome, Italy, by NewsRx correspondents, research stated, "Malignant mesothelioma (MM) is a tumor arising from mesothelium. MM patients' survival is poor."

Our news editors obtained a quote from the research from the University of Rome Sapienza, "The polyphenol 4',5,7,-trihydroxyflavone Apigenin (API) is a 'multifunctional drug'. Several studies have demonstrated API anti-tumoral effects. However, little is known on the and anti-tumoral effects of API in MM. Thus, we analyzed the effects of API on cell proliferation, cell cycle regulation, pro-survival signaling pathways, apoptosis, and autophagy of human and mouse MM cells. We evaluated the anti-tumor activities of API in mice transplanted with MM #40a cells forming ascites. API inhibited MM cells survival, increased reactive oxygen species intracellular production and induced DNA damage. API activated apoptosis but not autophagy. API-induced apoptosis was sustained by the increase of Bax/Bcl-2 ratio, increase of p53 expression, activation of both caspase 9 and caspase 8, cleavage of PARP-1, and increase of the percentage of cells in subG1 phase. API treatment affected the phosphorylation of ERK1/2, JNK and p38 MAPKs in a cell-type specific manner, inhibited AKT phosphorylation, decreased c-Jun expression and phosphorylation, and inhibited NF-kB nuclear translocation. Intraperitoneal administration of API increased the median survival of C57BL/6 mice intraperitoneally transplanted with #40a cells and reduced the risk of tumor growth."

According to the news editors, the research concluded: "Our findings may have important implications for the design of MM treatment using API."

For more information on this research see: In Vitro and In Vivo Anti-tumoral Effects of the Flavonoid Apigenin in Malignant Mesothelioma. Frontiers In Pharmacology, 2017;8():373 (see also Oncology - Malignant Mesothelioma).

The news editors report that additional information may be obtained by contacting L. Masuelli, Dept. of Experimental Medicine, University of Rome Sapienza, Rome, Italy. Additional authors for this research include M. Benvenuto, R. Mattera, E. Di Stefano, E. Zago, G. Taffera, I. Tresoldi, M.G. Giganti, G.V. Frajese, G. Berardi, A. Modesti and R. Bei.

Keywords for this news article include: Rome, Italy, Europe, Cancer, Caspase, Genetics, Oncology, Apoptosis, Enzymes and Coenzymes, Malignant Mesothelioma.

Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2017, NewsRx LLC

Articles featured in Life Extension Daily News are derived from a variety of news sources and are provided as a service by Life Extension. These articles, while of potential interest to readers of Life Extension Daily News, do not necessarily represent the opinions nor constitute the advice of Life Extension.